Intra-Cellular Therapies, Inc. (ITCI)
Largest Insider Buys in Sector
ITCI Stock Price History Chart
ITCI Stock Performance
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as …
Insider Activity of Intra-Cellular Therapies, Inc.
Over the last 12 months, insiders at Intra-Cellular Therapies, Inc. have bought $0 and sold $69.8M worth of Intra-Cellular Therapies, Inc. stock.
On average, over the past 5 years, insiders at Intra-Cellular Therapies, Inc. have bought $4.11M and sold $35.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 99,000 shares for transaction amount of $2.93M was made by Alafi Christopher D (director) on 2020‑09‑14.
List of Insider Buy and Sell Transactions, Intra-Cellular Therapies, Inc.
| 2024-08-30 | Sale | Chairman and CEO | 34,396 0.0324% | $72.84 | $2.51M | +1.94% | ||
| 2024-08-29 | Sale | Chairman and CEO | 35,604 0.0338% | $72.57 | $2.58M | +3.38% | ||
| 2024-08-28 | Sale | Chairman and CEO | 32,699 0.0309% | $72.75 | $2.38M | +2.45% | ||
| 2024-08-27 | Sale | Chairman and CEO | 40,513 0.0382% | $73.58 | $2.98M | +0.72% | ||
| 2024-08-26 | Sale | Chairman and CEO | 22,713 0.0215% | $74.59 | $1.69M | -0.46% | ||
| 2024-08-23 | Sale | Chairman and CEO | 28,680 0.0271% | $74.46 | $2.14M | -0.09% | ||
| 2024-08-22 | Sale | Chairman and CEO | 39,380 0.0374% | $74.68 | $2.94M | +0.11% | ||
| 2024-08-21 | Sale | Chairman and CEO | 53,013 0.0501% | $75.65 | $4.01M | -1.69% | ||
| 2024-08-16 | Sale | EVP, Chief Commercial Officer | 18,714 0.0178% | $75.08 | $1.41M | +0.83% | ||
| 2024-06-24 | Sale | director | 4,462 0.0042% | $75.57 | $337,193 | -0.91% | ||
| 2024-06-18 | Sale | director | 20,000 0.0208% | $75.91 | $1.52M | -0.72% | ||
| 2024-03-11 | Sale | Chairman, President & CEO | 20,565 0.0212% | $65.21 | $1.34M | +10.75% | ||
| 2024-03-11 | Sale | EVP, Chief Commercial Officer | 7,345 0.0076% | $65.61 | $481,931 | +10.75% | ||
| 2024-03-11 | Sale | EVP, Chief Medical Officer | 3,712 0.0038% | $65.59 | $243,482 | +10.75% | ||
| 2024-03-11 | Sale | SVP of Finance, CFO | 10,121 0.0105% | $65.96 | $667,587 | +10.75% | ||
| 2024-03-11 | Sale | EVP and General Counsel | 7,345 0.0076% | $65.97 | $484,537 | +10.75% | ||
| 2024-03-07 | Sale | Chairman, President & CEO | 40,712 0.0419% | $66.50 | $2.71M | +8.53% | ||
| 2024-03-07 | Sale | EVP, Chief Commercial Officer | 13,132 0.0135% | $66.57 | $874,179 | +8.53% | ||
| 2024-03-07 | Sale | EVP, Chief Medical Officer | 6,450 0.0066% | $66.56 | $429,308 | +8.53% | ||
| 2024-03-07 | Sale | SVP of Finance, CFO | 13,132 0.0135% | $66.60 | $874,560 | +8.53% |
Insider Historical Profitability
| RIGGS RORY B | director | 116600 0.11% | $88.86 | 2 | 2 | +11.52% |
| VAN NOSTRAND ROBERT L | director | 9690 0.0091% | $88.86 | 1 | 4 | +35.53% |
| Halstead Michael | EVP and General Counsel | 0 0% | $88.86 | 2 | 29 | +67.15% |
| ALAFI MOSHE | 10 percent owner | 3953270 3.7289% | $88.86 | 12 | 1 | +49.4% |
| ALAFI CAPITAL CO LLC | 10 percent owner | 3953270 3.7289% | $88.86 | 12 | 0 | +49.4% |
Institutional Investor Ownership
| Fidelity Investments | $774.67M | 10.6 | 11.19M | -2.3% | -$18.21M | 0.05 | |
| The Vanguard Group | $638.44M | 8.74 | 9.23M | +1.45% | +$9.11M | 0.01 | |
| BlackRock | $558.98M | 7.65 | 8.08M | -1.41% | -$8.01M | 0.01 | |
| Wasatch Advisors | $266.75M | 3.65 | 3.85M | +6.27% | +$15.74M | 1.4 | |
| Bellevue Group | $195.11M | 2.67 | 2.82M | -8.05% | -$17.09M | 2.99 |